EXEL vs TAK
Exelixis vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | EXEL | TAK |
|---|
| AI Score |
67
|
67
|
| Price |
$51.30
|
$17.49
|
| P/E Ratio |
15.60×
|
48.87×
|
| ROE |
36.2%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
62.1%
|
| Debt / Equity |
0.09×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
41.0
|
61.6
|
| Beta |
0.422
|
0.088
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TAK.
The committee scores are tied.
EXEL and TAK both score 67/100.
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical